Investor

Jeito Capital Becomes a Significant Investor in HI-Bio, a Clinical-Stage Biotechnology Company Developing Targeted Therapies for Patients with Serious Immune-Mediated Diseases

Jeito Capital

Jeito Capital becomes an important investWhere in HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases

Paris, France, November 1st 2022 – Jeito Capital (“Jeito”), a leading independent international biopharmaceutical private equity firm, today announced its participation in the $120 million financing of Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing therapies for patients with severe immune-mediated diseases (IMDs). Jeito Capital joins a syndicate of world-class investors, including ARCH Venture Partners and Monograph Capital, to back the San Francisco-based company.

Investment in HI-Bio is Jeito’s 11e to date and its first in the United States, demonstrating the fund’s ambition to build a global and diversified portfolio of companies operating in many therapeutic areas where patient needs are unmet and at different stages of development (from preclinical to advanced clinical stage).

HI-Bio has several clinical-stage programs and a strong translational platform with the potential to address multiple diseases with unmet medical needs. Few targeted therapies exist for patients with MI, which include autoimmune, allergic, and inflammatory diseases. Conventional therapies generally act on a large scale and do not address the root cause of the disease. As a result, many patients with MI experience limited symptom relief and may experience unnecessary side effects.

Nearly 4% of the world’s population is potentially affected by one of these diseases, and more than half of the people treated with currently available therapies are not in remission. With such large unmet medical needs, the global therapeutic market for these diseases could reach $150 billion by 2025.

Many IMDs arise from malfunctioning cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes, including antibody secretion, signaling mediators, tissue repair, and allergic responses. HI-Bio’s programs apply a precision medicine approach to target, modulate or deplete these cellular drivers of disease with therapeutics.

Doctor Rafaelle Tordjmanfounder and CEO of Jeito, commented: “Jeito’s investment in HI-Bio, alongside distinguished investors such as ARCH Venture Partners and Monograph Capital, represents an important milestone as we make our first investment in the United States, demonstrating our ambition to support businesses organizations developing breakthrough therapies in areas of high unmet need. HI-Bio is launching with a team of renowned experts with an impressive track record and a pipeline of precision therapies that have the potential to address the unmet needs of patients around the world today.

Rachel Mears, Partner at Jeito, added“Jeito’s investment supports HI-Bio’s important work for patients with immune-mediated diseases. The potential to reduce the enormous health burden on these patients through HI-Bio’s precision medicine approach was a key motivation for this investment. With HI-Bio’s ongoing clinical programs and its strong pipeline of additional development candidates, Jeito’s strategy to invest in strong teams grounded in quality science and positioned for growth focused on making a difference for patients will together with HI-Bio.

Travis Murdoch, MD, CEO of HI-Bio concluded“At HI-Bio, we embody the urgent need to develop more targeted precision therapies for patients suffering from immune-mediated diseases. Immune-mediated diseases represent a landscape where the scale of unmet need and potential benefit to patients is truly enormous. We are grateful to our investors Jeito Capital, ARCH and Monograph who share our vision for HI-Bio. They see that we have a concrete opportunity to bring an unprecedented degree of precision and creativity to clinical immunology, with all the potential improvements in safety and efficiency that come with our approach.

About Jeito Capital
Jeito Capital is a leading global investment firm with a patient-benefit approach that funds and accelerates the development and growth of breakthrough medical innovations. Jeito empowers and supports entrepreneurs through its expert, integrated and versatile team and through the investment of significant capital to ensure business growth, building market leaders in their respective therapeutic areas with accelerated patient access in the world, especially in Europe and the United States. states. Jeito Capital has €534 million under management and a rapidly growing investment portfolio. Jeito Capital is based in Paris with a presence in Europe and the United States.

@Jeito_lifeLinkedIn For more information, please visit www.jeito.life or follow @Jeito_life on Twitter or LinkedIn.

For more information, please contact :

Jeito Capital
Rafaelle Tordjman
Assia Mouhout, Pennsylvania
[email protected]
Tel: +33 6 76 49 37 94

Consilium Strategic Communications

Mary-Jane Elliott / Davide Salvi / Kris Lam

[email protected]

Tel: +44 (0) 20 3709 5700

Attachment